Harmony Biosciences Holdings, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Harmony Biosciences Holdings, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 443.6 times. Higher than almost all Healthcare companies in United States.
- Debt Due Cover Ratio: Debt due within a year is covered 17.4 times by its yearly operating cash. Higher than 88% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 3 of the last 3 years; profit grew in 2 of 3. Steadier than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$182Over the last 3 years, every $100 of reported profit came with $182 of operating cash.
Higher than 68% of Healthcare companies in United States.
Self-Funding Ratio
100×+Over the last 3 years its own operating cash covered its investment spending (capex) 443.6 times.
Higher than almost all Healthcare companies in United States.
Cash Locked Ratio
$10For every $100 of sales, $10 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $13 tied up three years earlier.
Less money tied up than 81% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
−$5Sales grew 98% in 3 years, but profit fell: $5 less profit per $100 of extra sales.
Lower than 72% of Healthcare companies in United States.
Asset Productivity Ratio
+98% / +89%In 3 years sales changed by +98% while total assets changed by +89%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
17.4×Debt due within a year is covered 17.4 times by its yearly operating cash.
Higher than 88% of Healthcare companies in United States.
Cash Cushion Ratio
+29%Cash, after subtracting all debt, equals 29% of its market value (net cash).
Higher than 68% of Healthcare companies in United States.
Tangible Assets Ratio
93%Of every $100 the company owns, $93 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 67% of Healthcare companies in United States.
Tangible Net Worth Ratio
90%Of every $100 of net worth, $90 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 71% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Harmony Biosciences Holdings, Inc. owes $0.27 for every $1 it owns. Net profit rose 9% in the year to Dec 2025, and shrank 4% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
11.6Investors pay $11.6 for every $1 of Harmony Biosciences Holdings, Inc.'s yearly profit, lower than 79% of Healthcare companies in United States.
P/B ratio
2.10The share price is 2.10 times Harmony Biosciences Holdings, Inc.'s book value per share, lower than 57% of Healthcare companies in United States.
Market cap
$2.1 BThe total market value of all of Harmony Biosciences Holdings, Inc.'s shares at today's price (share price × number of shares), larger than 76% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$999 MWhat Harmony Biosciences Holdings, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$17.16Net worth divided by the number of shares. The share price of $36.03 is 2.1 times this, which is the P/B above.
Return on equity (ROE)
20.5%Harmony Biosciences Holdings, Inc. earned 20.5% on its shareholders' money over the last year, higher than 90% of Healthcare companies in United States.
Owes vs Owns
0.27×Harmony Biosciences Holdings, Inc. owes $0.27 for every $1 it owns (low), lower than 63% of Healthcare companies in United States.
Dividend yield
NoneHarmony Biosciences Holdings, Inc. does not currently pay a dividend.
Revenue growth
+22%Revenue rose 22% in the year to Dec 2025, and grew 26% a year on average over 3 years.
Profit growth
+9%Net profit rose 9% in the year to Dec 2025, and shrank 4% a year on average over 3 years.
Profit margin
18.3%Harmony Biosciences Holdings, Inc. keeps $18 of every $100 of revenue as net profit.
Cash quality
2.2×Cash from Harmony Biosciences Holdings, Inc.'s business was 2.2× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
14.2×Harmony Biosciences Holdings, Inc.'s operating profit covered its interest costs 14.2 times in the year to Dec 2025.
Cash vs debt
Net cashHarmony Biosciences Holdings, Inc. held $612 M more cash than debt (net cash) at Dec 2025.
Questions
What is Harmony Biosciences Holdings, Inc.'s P/E ratio?
Investors pay $11.6 for every $1 of Harmony Biosciences Holdings, Inc.'s yearly profit, lower than 79% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Harmony Biosciences Holdings, Inc.: $2.1 B ÷ $999 M (30 Jun 2026) = 2.1.
What is Harmony Biosciences Holdings, Inc.'s return on equity?
Harmony Biosciences Holdings, Inc. earned 20.5% on its shareholders' money over the last year, higher than 90% of Healthcare companies in United States.
How much does Harmony Biosciences Holdings, Inc. owe compared with what it owns?
Harmony Biosciences Holdings, Inc. owes $0.27 for every $1 it owns (low), lower than 63% of Healthcare companies in United States.
Does Harmony Biosciences Holdings, Inc. pay a dividend?
No. Harmony Biosciences Holdings, Inc. does not currently pay a dividend.
Is Harmony Biosciences Holdings, Inc.'s revenue growing?
Revenue rose 22% in the year to Dec 2025, and grew 26% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.